XMetA originated from the anti-InsR antibody program and was selected as a partial activator of the human insulin receptor. They are fully human, high-affinity, allosteric monoclonal antibodies that selectively modulate the insulin receptor (INSR).
Structurally unrelated to insulin, XMetA antibodies bind the INSR at a different site than insulin and do not significantly interfere with insulin binding. This drug candidate therefore has utility countering hyperglycemia – i.e. it lowers blood glucose – and thus can be used alone or in combination with insulin or other approved drugs for treating diabetic conditions.
XMetA is designed to provide long-acting reduction of hyperglycemia in Type 2 diabetic patients, potentially reducing the advancement to a number of insulin injections needed to control their blood glucose levels.